CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2025
0mins
Source: Globenewswire
CytomX Therapeutics Offering: CytomX Therapeutics announced a public offering of 76,923,076 shares of common stock at $1.30 per share, aiming to raise approximately $100 million for research and development, corporate purposes, and working capital.
Company Overview: CytomX is focused on developing conditionally activated biologic therapeutics for cancer treatment, with a pipeline that includes innovative therapies such as CX-2051 and CX-801, and collaborations with major oncology firms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
